Cancer Therapy
Phase III data shows Tarceva plus gemcitabine significantly improves survival
Published in Obesity and Diabetes Week, February 21st, 2005
OSI Pharmaceuticals, Inc., (OSIP), Genentech, Inc., (DNA), and Roche (SWX Zurich) announced that a randomized, phase III, clinical study of Tarceva (erlotinib) plus gemcitabine chemotherapy in patients with locally advanced or metastatic pancreatic cancer met its primary endpoint by demonstrating a statistically significant 23.5% improvement in overall survival when compared to patients receiving gemcitabine plus placebo.
The data were presented at the second annual Gastrointestinal Cancers Symposium in Hollywood, Florida. According to the companies, Tarceva is the first drug shown in a phase III trial to prolong survival when added to the standard of care (gemcitabine)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Therapy
Amylin agonists show promise for diabetes treatment - Diabetes Therapy
Oral diabetes treatment reviewed - Diet & Nutrition
Low-carbohydrate/high-fat diet improves glucoregulation in diabetes - Heart Disease
Cardiovascular disease in diabetes reviewed - Leptin Studies
Metformin inhibits leptin via protein kinase signaling pathway - Adipose Tissue
Nuclear factor 1 regulates adipose tissue expression in GLUT4 gene - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
